Anti-interleukin 6 receptor antibody treatment in rheumatic disease | Annals of the Rheumatic Diseases

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Archive
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Department GEZ-LTA Erasmushogeschool

Article info

Article

Anti-interleukin 6 receptor antibody treatment in rheumatic disease

Authors

Norihiro Nishimoto aDepartment of Medical Science I, School of Health and Sport Sciences, Osaka University, 2–1 Yamada-oka, Suita City, Osaka 565–0871, Japan, bOsaka University, Osaka PubMed articles Google scholar articles
Tadamitsu Kishimoto aDepartment of Medical Science I, School of Health and Sport Sciences, Osaka University, 2–1 Yamada-oka, Suita City, Osaka 565–0871, Japan, bOsaka University, Osaka PubMed articles Google scholar articles
Kazuyuki Yoshizaki aDepartment of Medical Science I, School of Health and Sport Sciences, Osaka University, 2–1 Yamada-oka, Suita City, Osaka 565–0871, Japan, bOsaka University, Osaka PubMed articles Google scholar articles

Dr Nishimoto (norihiro{at}imed3.med.Osaka-u.ac.jp)

Citation

Nishimoto N, Kishimoto T, Yoshizaki K

Anti-interleukin 6 receptor antibody treatment in rheumatic disease

Annals of the Rheumatic Diseases 2000;59:i21-i27.

Publication history

First published November 1, 2000.

Online issue publication

January 09, 2022

Copyright information

Annals of the Rheumatic Diseases